Medicool Technologies

MediCool Technologies is a medical device startup developing Cool Cardioversion, a non-painful cryotherapy-based therapy to prevent and terminate dangerous cardiac arrhythmias, with an initial focus on atrial fibrillation — a condition affecting over 6 million Americans. Unlike standard-of-care electrical cardioversion, which causes significant pain, MediCool's approach uses cold to restore normal heart rhythm without shocks. The company has demonstrated feasibility in pre-clinical studies and first-in-human surgical implant cases and is advancing toward US clinical trials, led by a clinical team from Mayo Clinic.